CAMKMT

Across TCGA pan-cancer cohorts, CAMKMT mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CAMKMT data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CAMKMT mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CAMKMT expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where CAMKMT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	1.000	0.817	.013	9	view →
PDAC	OS	Median	IV	0.643	0.836	.038	6	view →
LSCC	OS	Median	All	0.800	1.000	.044	2	view →
HNSC	OS	Quartile	All	0.885	0.702	.049	1	view →
LUAD	OS	Median	II,III,IV	0.868	0.953	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CAMKMT–CCRCC (OS)

Open the CCRCC breakdown →